Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street?

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best small-cap stocks with huge growth potential. On February 18, Evercore ISI resumed coverage of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) with a Buy rating and set a price target of $17.00. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) also received a rating update from Bank of America Securities on January 27, which reaffirmed a Buy rating on the stock with a price target of $15.

In a separate development, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) announced on January 23 the completion of its acquisition of Astria Therapeutics, Inc., which was initially announced on October 14, 2025. Management stated that the transaction bolsters the company’s position as a leader in hereditary angioedema (HAE) and boosts its long-term growth trajectory.

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) adds navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development, to its HAE portfolio, which is positioned to considerably improve the treatment experience for HAE patients due to its potential to be the first HAE therapy with every-three and every-six month dosing and a high level of attack control. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) also obtained Astria’s early-stage program for atopic dermatitis, STAR0310, for which it has plans to pursue strategic alternatives.

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is a biotechnology company that provides structure-guided drug design to develop oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases.